Mark Lackner, Ph.D.

Mark Lackner, Ph.D.

Former Chief Scientific OfficeratZentalis Pharmaceuticals· In proxies 2024–2025

Pay in FY2025-74% from the year before · Zentalis Pharmaceuticals stock -55.4% the same year

Mark Lackner, Ph.D. was paid $1.2M in FY2025 (Dec), down 74%. Zentalis Pharmaceuticals stock fell 55.4% that year.

Pay$100 in the stock at the end of FY23 → $9
Pay is from the Summary Compensation Table of each Zentalis Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Zentalis PharmaceuticalsPublic company · 2 yr
    • Former Chief Scientific Officer2024 – Present · 2 yrStock in role -87%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?